Ahorhorlu Samuel Yao, Quashie Neils Ben, Jensen Rasmus Weisel, Kudzi William, Nartey Edmund Tetteh, Duah-Quashie Nancy Odurowah, Zoiku Felix, Dzudzor Bartholomew, Wang Christian William, Hansson Helle, Alifrangis Michael, Adjei George Obeng
Centre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School, University of Ghana, P.O. Box 4236, Accra, Ghana.
West African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana.
Malar J. 2023 Feb 19;22(1):58. doi: 10.1186/s12936-023-04482-w.
Artemisinin-based combination therapy (ACT) is the first-line treatment for uncomplicated malaria in Ghana. Artemisinin (ART) tolerance in Plasmodium falciparum has arisen in Southeast Asia and recently, in parts of East Africa. This is ascribed to the survival of ring-stage parasites post treatment. The present study sought to assess and characterize correlates of potential ART tolerance based on post-treatment parasite clearance, ex vivo and in vitro drug sensitivity, and molecular markers of drug resistance in P. falciparum isolates from children with uncomplicated malaria in Ghana.
Six months to fourteen years old children presenting with acute uncomplicated malaria (n = 115) were enrolled in two hospitals and a Health Centre in Ghana's Greater Accra region and treated with artemether-lumefantrine (AL) according to body weight. Pre- and post-treatment parasitaemia (day 0 and day 3) was confirmed by microscopy. The ex vivo ring-stage survival assay (RSA) was used to detect percent ring survival while the 72 h SYBR Green I assay was used to measure the 50% inhibition concentration (IC) of ART and its derivatives and partner drugs. Genetic markers of drug tolerance /resistance were evaluated using selective whole genome sequencing.
Of the total of 115 participants, 85 were successfully followed up on day 3 post-treatment and 2/85 (2.4%) had parasitaemia. The IC values of ART, artesunate (AS), artemether (AM), dihydroartemisinin (DHA), amodiaquine (AQ), and lumefantrine (LUM) were not indicative of drug tolerance. However, 7/90 (7.8%) pre-treatment isolates had > 10% ring survival rates against DHA. Of the four isolates (2 RSA positive and 2 RSA negative) with high genomic coverage, P. falciparum (Pf) kelch 13 K188* and Pfcoronin V424I mutations were only present in the two RSA positive isolates with > 10% ring survival rates.
The observed low proportion of participants with day-3 post-treatment parasitaemia is consistent with rapid ART clearance. However, the increased rates of survival observed in the ex vivo RSA against DHA, maybe a pointer of an early start of ART tolerance. Furthermore, the role of two novel mutations in PfK13 and Pfcoronin genes, harboured by the two RSA positive isolates that had high ring survival in the present study, remains to be elucidated.
以青蒿素为基础的联合疗法(ACT)是加纳治疗非复杂性疟疾的一线疗法。恶性疟原虫对青蒿素(ART)的耐受性已在东南亚出现,最近在东非部分地区也有出现。这归因于治疗后环状体期寄生虫的存活。本研究旨在根据治疗后寄生虫清除情况、体外和体内药物敏感性以及加纳非复杂性疟疾患儿恶性疟原虫分离株中耐药性的分子标记,评估和表征潜在青蒿素耐受性的相关因素。
在加纳大阿克拉地区的两家医院和一个健康中心招募了6个月至14岁患有急性非复杂性疟疾的儿童(n = 115),并根据体重给予蒿甲醚 - 本芴醇(AL)治疗。通过显微镜检查确认治疗前和治疗后的寄生虫血症(第0天和第3天)。采用体外环状体期存活试验(RSA)检测环状体存活率百分比,同时使用72小时SYBR Green I试验测量青蒿素及其衍生物和联合药物的50%抑制浓度(IC)。使用选择性全基因组测序评估药物耐受性/耐药性的遗传标记。
在总共115名参与者中,85名在治疗后第3天成功随访,其中2/85(2.4%)有寄生虫血症。青蒿素、青蒿琥酯(AS)、蒿甲醚(AM)、双氢青蒿素(DHA)、阿莫地喹(AQ)和本芴醇(LUM)的IC值未表明存在药物耐受性。然而,90份治疗前分离株中有7/90(7.8%)对DHA的环状体存活率>10%。在4份基因组覆盖率高的分离株(2份RSA阳性和2份RSA阴性)中,恶性疟原虫(Pf)kelch 13 K188*和Pfcoronin V424I突变仅存在于2份RSA阳性分离株中,其环状体存活率>10%。
观察到治疗后第3天有寄生虫血症的参与者比例较低,这与青蒿素的快速清除一致。然而,体外RSA中观察到的针对DHA的存活率增加,可能是青蒿素耐受性早期开始的一个指标。此外,本研究中两份RSA阳性分离株所携带的PfK13和Pfcoronin基因中的两个新突变的作用,仍有待阐明。